



SUPPLEMENTARY DATA

Supplementary Figure 1. Time course of change in plasma glucose concentration in the three treatment groups.




SUPPLEMENTARY DATA

Supplementary Figure 2. Plasma glucose concentration during the EGP measurement at baseline (closed circles) and at 16 weeks (open circles) in subjects received canagliflozin (A), liraglutide (B) and canagliflozin plus liraglutide (C).



SUPPLEMENTARY DATA

Supplementary Figure 3. The relationship between the amount of glucose returned to the circulation over 24 hours (calculated from the change in bEGP) and the amount of glucose excreted in the urine.



SUPPLEMENTARY DATA

Supplementary Table 1. baseline patient characteristics

	Canagliflozin	Liraglutide	Canagliflozin/ Liraglutide	P- value
Number	15	15	15	
Age (years)	53±2	53±2	51±3	NS
Gender (m)	10	8	6	NS
Diabetes Duration (y)	7.3±1.6	7.1±1.4	8.3±1.4	NS
BMI (kg/m ²)	34.8±1.7	35.1±1.1	34.8±1.1	NS
FPG (mg/dl)	174±12	177±10	180±15	NS
HbA1c (%)	8.2±0.3	8.4±0.3	8.1±0.3	NS
eGFR (ml/min)	97±6	105±5	92±6	NS
Systolic Blood Pressure (mmHg)	134±2	131±2	136±4	NS
Diastolic Blood Pressure (mmHg)	80±3	79±2	80±3	NS
Pulse	70±3	76±2	76±3	NS
Background Medications				
Drug Naïve	2	1	2	
Metformin	8	9	9	
Metformin/SU	5	5	4	